ArticleFrontiers in cell and developmental biology2026
Demethylation of leptin promoter in gestational diabetes mellitus: evidence from a mouse model.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational diabetes mellitus (GDM) has been linked to altered leptin (LEP) gene methylation, which may disrupt maternal glucose metabolism and the associated placental signaling. However, the changes of LEP methylation involved in GDM pathophysiology throughout pregnancy remain unclear. Methods: Female C57BL/6J mice (6-8 weeks old) were randomly divided into control and GDM groups (n = 40 each). The GDM group was fed a high-fat diet for 4 weeks before mating and given a single streptozotocin injection (120 mg/kg, intraperitoneal injection) on gestational day 2, while controls received standard chow and citrate buffer. Fasting blood glucose and body weight were recorded at baseline, gestational days 5, 12, and 18, and postpartum day 1. Oral glucose tolerance tests (OGTTs) were performed at corresponding stages. Blood was collected for measurement of serum leptin concentrations by ELISA. Leptin protein expression and LEP promoter methylation in decidual tissues were analyzed by Western blot and bisulfite pyrosequencing, respectively. Weighted least-squares regression was used to evaluate the associations between leptin, LEP promoter methylation, and glucose metabolism. Results: The high-fat diet and streptozotocin (HFD + STZ) combination successfully induced a GDM phenotype, as evidenced by early and persistent hyperglycemia and impaired glucose tolerance. Serum leptin levels were significantly increased in GDM mice before pregnancy and returned to the levels of pre-pregnancy in postpartum, indicating that the decidua plays an important role in the dynamic regulation of leptin during pregnancy. Western blot analysis confirmed higher leptin expression in the decidual tissue of GDM mice, while bisulfite pyrosequencing revealed significant demethylation of the LEP promoter. WLS analysis showed that leptin upregulation in GDM was closely associated with epigenetic remodeling at specific CpG sites within the LEP promoter, whereas the relationship between promoter demethylation and FBG was altered in GDM. Conclusion: Decidual LEP promoter demethylation is associated with hyperleptinemia and shows an epigenetic mechanism linking GDM. LEP promoter demethylation may reflect the metabolic disturbance in GDM and serve as a potential early marker for GDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.